Barry Buckland obtained a PhD in Biochemical Engineering from University College London. During his 28 years at Merck Research Laboratories, he led the process development and transfer of technology to manufacturing for many key new vaccines including Hepatitis A, Rotavirus, HPV, Shingles, Chicken Pox, and pneumonia. Since leaving Merck 12 years ago Barry has worked as an independent consultant including with Protein Sciences to develop an FDA licensed protein based recombinant influenza vaccine. He is now Executive Director of NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) as well as a Visiting professor at University College London.
